Uncategorized

Cell therapy biotech Obsidian leverages Galera reverse merger to go public

Published

2 months ago

on

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a partner via a reverse merger with Obsidian Therapeutics that will take oncology-focused Obsidian public.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version